Cost-effectiveness analysis of tandem mass spectrometry compared to fluorescence analysis for screening neonatal genetic metabolic diseases
While MS/MS screening incurs higher costs, it achieves significantly greater QALY gains and demonstrates favorable cost-effectiveness and economic benefits. MS/MS screening should be actively promoted for neonatal IMDs in China.
Authors
- Bin Luo (ORCID: https://orcid.org/0000-0002-3502-3769)
- Zhen Huang (ORCID: https://orcid.org/0000-0002-3990-7350)
- Yingyao Chen (ORCID: https://orcid.org/0000-0002-3470-0748)
- Siyun Zhou
- Julie Weng
- Dunming Xiao
Institutions
- Fudan University (CN)
- National Health and Family Planning Commission (CN)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1186/s12913-025-12419-z
- Citations
- 1
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.32